GlassScriptPhysician profile
Michelle Lisgaris
NPI 1881614576
$4,145.59
in general payments reported to CMS, 2019-2025
19 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $534 · 2021: $305 · 2022: $434 · 2023: $703 · 2024: $382 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $855.45 | 2019-2025 | Veklury, Biktarvy |
| Janssen Biotech, INC. | $824.37 | 2019-2023 | Symtuza |
| Janssen Products, LP | $565.31 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $437.34 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Insmed, INC. | $303.47 | 2019-2025 | Arikayce |
| Melinta Therapeutics, LLC | $268.28 | 2019-2024 | Vabomere, Orbactiv, Kimyrsa |
| Theratechnologies INC. | $194.60 | 2019 | |
| Shionogi INC | $181.98 | 2023-2025 | Fetroja |
| Viiv Healthcare Company | $118.03 | 2019-2024 | Cabenuva, Dovato |
| Astellas Pharma US INC | $91.36 | 2022-2024 | Cresemba |
| Napo Pharmaceuticals INC | $88.23 | 2019-2024 | Mytesi |
| Abbvie INC. | $41.79 | 2024 | |
| Allergan, INC. | $40.98 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $30.22 | 2019 | |
| Amryt Pharma Holdings LTD | $24.65 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $23.10 | 2025 | Zevtera |
| Bavarian Nordic A/S | $20.06 | 2025 | Vivotif |
| Angiodynamics, INC. | $18.30 | 2020 | |
| Ferring Pharmaceuticals INC. | $18.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Lisgaris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.